Vivek Subbiah: Grateful to have Jason Dorsey deliver a phenomenal and energetic keynote at the 27th Annual Scientific Meeting of SCRI!
Vivek Subbiah shared a post on LinkedIn:
“Grateful to have Jason Dorsey an acclaimed speaker, deliver a phenomenal and energetic keynote at the 27th Annual Scientific Meeting of SCRI!
So proud to have such visionary leaders at Sarah Cannon Research Institute Dee Anna Smith Skip Burris David R. Spigel driving strategic progress & inspiring us everyday in delivering clinical trials across communities. ”
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023